VIVUS is a biopharmaceutical company focused on improving the quality of life for patients with serious medical conditions, particularly in the areas of obesity, exocrine pancreatic insufficiency (EPI), and pulmonary arterial hypertension (PAH). One of their key products is PANCREAZE®, a pancreatic enzyme replacement therapy designed to manage EPI, a condition characterized by insufficient production of pancreatic enzymes, leading to symptoms such as chronic diarrhea and malnutrition. PANCREAZE® helps patients by providing the necessary enzymes to aid in digestion, thereby improving their overall health and nutritional status.

In addition to PANCREAZE®, VIVUS offers QSYMIA, a medication indicated for weight management in adults with obesity or overweight conditions accompanied by weight-related comorbidities. QSYMIA combines phentermine and topiramate to assist patients in achieving weight loss when used alongside a reduced-calorie diet and increased physical activity. The company has received marketing authorization for QSYMIA in several European countries, highlighting its commitment to addressing the therapeutic needs of patients across different regions. VIVUS continues to expand its product pipeline and regulatory approvals to enhance treatment options for patients with life-limiting diseases.

United States

VIVUS - With demonstrated clinical development and commercialization expertise, VIVUS is dedicated to addressing the therapeutic needs of patients with serious medical conditions and life-limiting diseases. We develop high-potential molecules that have compelling safety and efficacy potential, and transform them into proprietary products that enable significant advances in patient care and outcomes. We strive to meet our goals of improving patient quality of life, giving healthcare providers new treatment options, providing a collaborative environment for our employees and creating value for our shareholders.

VIVUS

Company Details